BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.

The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.

Otsuka subsidiary Astex plans filing in MDS by year-end for first oral decitabine product on the back of positive Phase III comparative results.

There are lots of growth opportunities and new regulatory initiatives for devices in India, affirms a report by o3 Capital Global Advisory Private Limited, an Indian investment banking firm. But device-related issues are not high on the agenda of FDA Commissioner Hamburg during her trip to the country concluding Feb. 18.